Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Organisation › Details

Cellinta Ltd.

Cellinta is a biotechnology company focused on developing highly selective gene therapies for cancer. Cellinta’s first-in-class gene therapies harnesses master regulators governing cell identity to deliver therapeutic agents selectively to cancer stem cells. The Company's platform leverages the expertise and recent discoveries across stem cell biology, synthetic biology and cancer genomics of its renowned founding scientist, Professor Steve Pollard from the University of Edinburgh, UK. This builds upon the advancements of viral vectors as a clinically validated and scalable platform to rapidly develop new treatments for patients. *


Period Start 2019-08-16 established (s-off)
  Predecessor University of Edinburgh
Product Industry gene therapy
Person Person Bekkali, Soraya (Cellinta 202007– CEO before Gyroscope Therapeutics + Lysogene + Orphan Europe + Sanofi)
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 71 Kingsway
  City WC2B 6ST London
    Address record changed: 2020-10-10
Basic data Employees n. a.
    * Document for �About Section�: Cellinta Ltd.. (9/15/20). "Press Release: Launch of Cellinta and Appointment of Dr Soraya Bekkali as CEO". London.
Record changed: 2020-10-10


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Cellinta Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top